
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Cell. Neurosci. , 02 July 2019
Sec. Cellular Neurophysiology
Volume 13 - 2019 | https://doi.org/10.3389/fncel.2019.00292
This article is part of the Research Topic From Cell Physiology to Emerging Brain Functions View all 16 articles
This article is a correction to:
Morphine Binds Creatine Kinase B and Inhibits Its Activity
A Corrigendum on
Morphine Binds Creatine Kinase B and Inhibits Its Activity
by Weinsanto, I., Mouheiche, J., Laux-Biehlmann, A., Delalande, F., Marquette, A., Chavant, V., et al. (2018). Front. Cell. Neurosci. 12:464. doi: 10.3389/fncel.2018.00464
In the published article, there was an error in affiliation “2.” Instead of “Global Drug Discovery, Global Therapeutic Research Groups, Gynecological Therapies, Bayer Healthcare, Berlin, Germany”, it should be “Laboratoire de Spectrométrie de Masse BioOrganique, IPHC-DSA, CNRS UMR7178 and Université de Strasbourg, Strasbourg, France.”
Additionally, the current address of one author has been added as a footnote and is denoted using “‡.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: morphine, complex, ligand-binding protein, creatine kinase, high affinity
Citation: Weinsanto I, Mouheiche J, Laux-Biehlmann A, Delalande F, Marquette A, Chavant V, Gabel F, Cianferani S, Charlet A, Parat M-O and Goumon Y (2019) Corrigendum: Morphine Binds Creatine Kinase B and Inhibits Its Activity. Front. Cell. Neurosci. 13:292. doi: 10.3389/fncel.2019.00292
Received: 13 June 2019; Accepted: 14 June 2019;
Published: 02 July 2019.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2019 Weinsanto, Mouheiche, Laux-Biehlmann, Delalande, Marquette, Chavant, Gabel, Cianferani, Charlet, Parat and Goumon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yannick Goumon, eWFubmljay5nb3Vtb25AaW5zZXJtLnUtc3RyYXNiZy5mcg==
†These authors have contributed equally to this work
‡Present Address: Alexis Laux-Biehlmann, Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.